(HealthDay News) — For patients with end-stage kidney disease (ESKD), those with concomitant psoriasis are younger and more often have cancer, diabetes mellitus, and coronary artery disease, according to a study published online in the Journal of Clinical Medicine.
Johannes Wild, MD, from the University Medical Center Mainz in Germany, and colleagues examined the impact of concomitant psoriasis on the in-hospital outcomes of patients hospitalized with ESKD. A total of 360,980 hospitalizations of patients treated for ESKD in German hospitals were identified from 2010 to 2020; 0.3% of these patients also suffered from psoriasis.
The researchers found that within the time period, the annual number of all ESKD patients increased, but slight decreases were seen in the number of patients with ESKD and psoriasis. Patients with ESKD and psoriasis were younger (66 vs 71 years), more often obese (17.5 vs 8.2%), and more often had cancer (4.9 vs 3.3%), diabetes mellitus (42.7 vs 38.5%), and coronary artery disease (31.1 vs 28.0%). For patients with ESKD, psoriasis was not associated with in-hospital case fatality in multivariate regression models.
“Taken together, our study results should be considered hypothesis-generating, and large prospective observational studies are needed to further explore the impact of psoriasis on different stages of acute and chronic kidney disease,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.